Improved immune response by ID-pVAC: a secretory DNA vaccine construct delivered by PLG micro particles against foot and mouth disease in guinea pigs.
Foot and mouth disease (FMD) outbreaks usually have devastating effects on the economy of countries were disease is endemic due to direct and indirect cost; most of them related to international trade embargoes of animals and animal products. Although currently used inactivated vaccine provides protection, it has several drawbacks like short duration of immunity, and the requirement for containment facilities. A DNA vaccine construct which expresses the secretary antigens, delivered through micro particles could be one of the alternate approaches to overcome these limitations. Present study is envisaged to prepare a DNA vaccine construct containing the VP1 sequence of FMDV serotype O in pVAC vector. DNA vaccine was formulated by adsorbing plasmid DNA construct on cationic micro particles and administered in guinea pigs @25 μg DNA vaccine construct per animal intramuscularly. Sera samples collected were analyzed by sandwich ELISA and SNT, shown enhanced immune response in PLG adjuvanted DNA vaccine. MTT and 3H Thymidine incorporation have shown good CMI responses to PLG adjuvanted DNA. When challenged with 100 gpid50 of homologous virus 5 of the six animals were protected.
Jadav
Sameer K
SK
Molecular Virology Lab, Indian Veterinary Research Institute, Bangalore, India.
Reddy
K Siva
KS
Molecular Virology Lab, Indian Veterinary Research Institute, Bangalore, India.
Rashmi
B R
BR
Molecular Virology Lab, Indian Veterinary Research Institute, Bangalore, India.
Dechamma
H J
HJ
Molecular Virology Lab, Indian Veterinary Research Institute, Bangalore, India.
Ganesh
K
K
Molecular Virology Lab, Indian Veterinary Research Institute, Bangalore, India.
Suryanarayana
V V S
VVS
Molecular Virology Lab, Indian Veterinary Research Institute, Bangalore, India.
Reddy
G R
GR
Molecular Virology Lab, Indian Veterinary Research Institute, Bangalore, India. Electronic address: drreddygr@gmail.com.
D000818:Animals; D004279:DNA, Viral; D004337:Drug Carriers / Q000008:administration & dosage*; D005536:Foot-and-Mouth Disease / Q000276:immunology* / Q000517:prevention & control; D006168:Guinea Pigs; D019344:Lactic Acid / Q000008:administration & dosage*; D008213:Lymphocyte Activation / Q000276:immunology; D052638:Particulate Matter / Q000008:administration & dosage; D010849:Picornaviridae / Q000276:immunology; D011100:Polyglycolic Acid / Q000008:administration & dosage*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D012376:Rodent Diseases / Q000276:immunology* / Q000517:prevention & control; D019444:Vaccines, DNA / Q000008:administration & dosage* / Q000276:immunology*
D004279:DNA, Viral; D004337:Drug Carriers; D052638:Particulate Matter; D019444:Vaccines, DNA; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid